UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.506

Sortiert nach

Comparison of overall survival of lisocabtagene maraleucel (liso‐cel) versus standard of care (SOC) adjusting for crossover in second‐line (2L) R/R large B‐cell lymphoma

Hematological oncology, 2023-06, Vol.41 (S2), p.451-452

2023

Volltextzugriff (PDF)

Budget impact analysis of introducing a non-reconstituted, hexavalent vaccine for pediatric immunization in the United Kingdom

Expert review of vaccines, 2020-12, Vol.19 (12), p.1167-1175

2020

Volltextzugriff (PDF)

Biologic treatment sequences for plaque psoriasis: a cost–utility analysis based on 10 years of Dutch real‐world evidence from BioCAPTURE

British journal of dermatology (1951), 2018-05, Vol.178 (5), p.1181-1189

2018

Volltextzugriff (PDF)

P1744: ACCURACY OF PREDICTING LONG‐TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B‐CELL LYMPHOMA (LBCL)

HemaSphere, 2022-06, Vol.6 (Suppl), p.1625-1626

2022

Volltextzugriff (PDF)

P46 Can Large Language Models Simulate HTA Committee Discussions? Findings and Challenges from a Case Study in Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer

Value in health, 2024-06, Vol.27 (6), p.S11-S11

2024

Volltextzugriff (PDF)

MSR80 AI-Enabled Risk of Bias Assessment of RCTs in Systematic Reviews: A Case Study

Value in health, 2023-12, Vol.26 (12), p.S408

2023

Volltextzugriff (PDF)

MSR78 Use of External Control Data to Adjust for Treatment Switching in Cost-Effectiveness Analyses: Lisocabtagene Maraleucel (Liso-Cel) Versus Standard of Care (SOC) in Second-Line Relapsed or Refractory Large B-Cell Lymphoma

Value in health, 2023-12, Vol.26 (12), p.S407-S408

2023

Volltextzugriff (PDF)

SA72 Current Practices for the Selection of Effect Modifiers and Confounders in Population-Adjusted Indirect Comparisons (PAIC): A Review of Technology Appraisals (TA)

Value in health, 2023-12, Vol.26 (12), p.S555

2023

Volltextzugriff (PDF)

MSR46 Breaking Through Limitations: Enhanced Systematic Literature Reviews With Large Language Models

Value in health, 2023-12, Vol.26 (12), p.S402

2023

Volltextzugriff (PDF)

Collaborating for Digital Transformation: How Internal and External Collaboration Can Contribute to Innovate Public Service Delivery

2024

Volltextzugriff (PDF)

Template‐Directed Synthesis of an Inverted Spiro Architecture

Chemistry : a European journal, 2018-09, Vol.24 (50), p.13114-13117

2018

Volltextzugriff (PDF)

MSR68 Variability and Improvements of Answers Generated with Different Versions of Large Language Models

Value in health, 2024-06, Vol.27 (6), p.S272-S272

2024

Volltextzugriff (PDF)

EE205 Automating Economic Modeling: Potential of Generative AI for Updating Modeling Reports

Value in health, 2024-06, Vol.27 (6), p.S95-S95

2024

Volltextzugriff (PDF)

MSR18 Improving the Performance of Generative AI to Achieve 100% Accuracy in Data Extraction

Value in health, 2024-06, Vol.27 (6), p.S262-S263

2024

Volltextzugriff (PDF)

P48 Automating Economic Modelling: Potential of Generative AI for Updating Excel-Based Cost-Effectiveness Models

Value in health, 2024-06, Vol.27 (6), p.S11-S11

2024

Volltextzugriff (PDF)

SA64 One-Step Parametric Network Meta-Analysis Models Using the Exact Likelihood That Allow for Time-Varying Treatment Effects

Value in health, 2024-06, Vol.27 (6), p.S406-S406

2024

Volltextzugriff (PDF)

P1 Automating Economic Modelling: A Case Study of AI's Potential With Large Language Models

Value in health, 2023-12, Vol.26 (12), p.S1

2023

Volltextzugriff (PDF)

P22 Disrupting Health Economics: Automating Network Meta-Analyses With AI and Large Language Models

Value in health, 2023-12, Vol.26 (12), p.S6

2023

Volltextzugriff (PDF)

Branding in Governance and Public Management

1, 2012

Volltextzugriff (PDF)

MSR31 Applying Multi-Level Network Meta-Regression (ML-NMR) to a Case Study in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Value in health, 2023-06, Vol.26 (6), p.S283-S283

2023

Volltextzugriff (PDF)

717P Comparison of long-term survival and cost-effectiveness (CE) of first-line (1L) treatment options in advanced renal cell carcinoma (aRCC) with intermediate or poor (I/P) prognostic risk

Annals of oncology, 2020-09, Vol.31, p.S563-S564

2020

Volltextzugriff (PDF)

PCN23 UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

Value in health, 2019-11, Vol.22, p.S439-S439

2019

Volltextzugriff (PDF)

PCN421 STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

Value in health, 2019-11, Vol.22, p.S517-S518

2019

Volltextzugriff (PDF)

POSA35 Lifetime Survival Estimates for Nivolumab+Ipilimumab and Sunitinib in Previously Untreated Patients with Advanced/Metastatic Intermediate- or Poor (I/P)-Risk Renal Cell Carcinoma (1L ARCC) Based on 5-Year Minimum Follow-up Data from CheckMate 214

Value in health, 2022-01, Vol.25 (1), p.S24-S24

2022

Volltextzugriff (PDF)

MS4 A COMPARISON OF THE PARTITIONED SURVIVAL AND MULTISTATE EXTRAPOLATION METHODS: A CASE STUDY BASED ON THE GASTRIC CANCER TRIAL ATTRACTION-2

Value in health, 2019-05, Vol.22, p.S41-S41

2019

Volltextzugriff (PDF)

1 – 25 von 2.506

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.205)
Mit Volltextzugriff
(2.287)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

IngentaConnect
(1.224)
EZB Electronic Journals Library
(1.134)
MEDLINE
(813)
IngentaConnect Journals
(724)
Ovid SocietyJournals and Single Titles
(685)
Elsevier ScienceDirect Journals
(454)
Publisher or Other Site
(377)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(283)
Wiley Journals
(278)
JSTOR
(244)
Springer Nature - Complete Springer Journals
(227)
Brill Online Journals
(173)
2022 Brill Journal Collection
(173)
Wiley Online Library Full Collection 2018
(164)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(146)
EBSCOhost Business Source Ultimate
(136)
SAGE Complete
(125)
Ebook Central Perpetual and DDA
(120)
eBooks on EBSCOhost
(113)
2023 Brill Journal Collection
(112)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Comparison of overall survival of lisocabtagene maraleucel (liso‐cel) versus standard of care (SOC) adjusting for crossover in second‐line (2L) R/R large B‐cell lymphoma

Budget impact analysis of introducing a non-reconstituted, hexavalent vaccine for pediatric immunization in the United Kingdom

Biologic treatment sequences for plaque psoriasis: a cost–utility analysis based on 10 years of Dutch real‐world evidence from BioCAPTURE

P1744: ACCURACY OF PREDICTING LONG‐TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B‐CELL LYMPHOMA (LBCL)

P46 Can Large Language Models Simulate HTA Committee Discussions? Findings and Challenges from a Case Study in Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer

MSR80 AI-Enabled Risk of Bias Assessment of RCTs in Systematic Reviews: A Case Study

MSR78 Use of External Control Data to Adjust for Treatment Switching in Cost-Effectiveness Analyses: Lisocabtagene Maraleucel (Liso-Cel) Versus Standard of Care (SOC) in Second-Line Relapsed or Refractory Large B-Cell Lymphoma

SA72 Current Practices for the Selection of Effect Modifiers and Confounders in Population-Adjusted Indirect Comparisons (PAIC): A Review of Technology Appraisals (TA)

MSR46 Breaking Through Limitations: Enhanced Systematic Literature Reviews With Large Language Models

Collaborating for Digital Transformation: How Internal and External Collaboration Can Contribute to Innovate Public Service Delivery

Template‐Directed Synthesis of an Inverted Spiro Architecture

MSR68 Variability and Improvements of Answers Generated with Different Versions of Large Language Models

EE205 Automating Economic Modeling: Potential of Generative AI for Updating Modeling Reports

MSR18 Improving the Performance of Generative AI to Achieve 100% Accuracy in Data Extraction

P48 Automating Economic Modelling: Potential of Generative AI for Updating Excel-Based Cost-Effectiveness Models

SA64 One-Step Parametric Network Meta-Analysis Models Using the Exact Likelihood That Allow for Time-Varying Treatment Effects

P1 Automating Economic Modelling: A Case Study of AI's Potential With Large Language Models

P22 Disrupting Health Economics: Automating Network Meta-Analyses With AI and Large Language Models

Branding in Governance and Public Management

MSR31 Applying Multi-Level Network Meta-Regression (ML-NMR) to a Case Study in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

717P Comparison of long-term survival and cost-effectiveness (CE) of first-line (1L) treatment options in advanced renal cell carcinoma (aRCC) with intermediate or poor (I/P) prognostic risk

PCN23 UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

PCN421 STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

POSA35 Lifetime Survival Estimates for Nivolumab+Ipilimumab and Sunitinib in Previously Untreated Patients with Advanced/Metastatic Intermediate- or Poor (I/P)-Risk Renal Cell Carcinoma (1L ARCC) Based on 5-Year Minimum Follow-up Data from CheckMate 214

MS4 A COMPARISON OF THE PARTITIONED SURVIVAL AND MULTISTATE EXTRAPOLATION METHODS: A CASE STUDY BASED ON THE GASTRIC CANCER TRIAL ATTRACTION-2

Suchergebnisse filtern